Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Trading Floor Community IconFrom the Trading Floor:
ARKG Holdings/CERS/
Cerus Corp. Logo

ARKG Holdings of Cerus Corporation (CERS) - Updated Daily

Lock IconJoin Premium Plan

Trades of CERS Made In ARKG

Why do the number of shares of a company held in an ARK ETF go up or down even when no trades are reported?

The Bucket Report Icon
The Bucket ReportSubscribe to get all the important numbers from the financial markets delivered to your inbox every trading day 📫
Date
Direction
Shares
Fund Weight
Fund
October 4, 2021BUY119.000k0.01%ARKG
  • 1
  • 5 / page

Key Statistics

🕵🏼Found In🏷Last Price
ARKGARKK$5.43
⚖️Weighting🧢Market Cap
0.66%$943.31m
🏋🏿‍♂️Weight Rank In ARKG🧮Price to Sales
397.21
🏋️‍♀️Weight Rank Across All Funds🌏Country
48🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$3.262.51%
Description
Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
Website
www.cerus.com

Research Notes and Commentary for CERS